Literature DB >> 8501323

Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli.

M E Evans1, M Pollack.   

Abstract

The ability of six antibiotics from different classes to release radiolabeled lipopolysaccharide (LPS) from a phenotypically smooth galE mutant of Escherichia coli O111:B4 was examined. Antibiotic concentrations were 0.0625-512 micrograms/mL. LPS release increased as a function of the antibiotic concentration, reaching a limit at or near the concentration that killed the majority of bacteria. The maximum amount of LPS released by polymyxin B was 40.6% +/- 0.9%, by gentamicin 58.2% +/- 2.5%, by ciprofloxacin 65.8% +/- 2.5%, by ceftazidime 73.1% +/- 0.9%, by tetracycline 75.3% +/- 10.0%, and by imipenem 79.7% +/- 2.3%. In timed experiments, ceftazidime released 61.9% +/- 1.2%, imipenem 51.1% +/- 8.8%, and tetracycline 39.7% +/- 4.4% of the LPS within the first hour of incubation, whereas polymyxin B released 13.5% +/- 1.9%, gentamicin 9.8% +/- 3.6%, and ciprofloxacin 12.7% +/- 2.6% of the LPS (P < .05). Fluoro-radiography and immunoblot analyses revealed similar migration patterns for antibiotic-released and cell-bound LPS on SDS-PAGE gels, suggesting similar O-polysaccharide content in the two LPS fractions. The amount and rate of LPS release from an E. coli strain was dependent upon antibiotic class and concentration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501323     DOI: 10.1093/infdis/167.6.1336

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar typhimurium msbB mutant.

Authors:  Qingke Kong; David A Six; Qing Liu; Lillian Gu; Kenneth L Roland; Christian R H Raetz; Roy Curtiss
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

Review 2.  The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G.

Authors:  D Xuan; D P Nicolau; P R Tessier; L Bow; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 4.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

5.  Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors.

Authors:  Lena Heinbockel; Susana Sánchez-Gómez; Guillermo Martinez de Tejada; Sabine Dömming; Julius Brandenburg; Yani Kaconis; Mathias Hornef; Aline Dupont; Sebastian Marwitz; Torsten Goldmann; Martin Ernst; Thomas Gutsmann; Tobias Schürholz; Klaus Brandenburg
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

6.  Identification of specific targets for the gut mucosal defense factor intestinal alkaline phosphatase.

Authors:  Kathryn T Chen; Madhu S Malo; Angela K Moss; Skye Zeller; Paul Johnson; Farzad Ebrahimi; Golam Mostafa; Sayeda N Alam; Sundaram Ramasamy; H Shaw Warren; Elizabeth L Hohmann; Richard A Hodin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-05-20       Impact factor: 4.052

7.  Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines.

Authors:  Tie Liu; Rolf König; Jian Sha; Stacy L Agar; Chien-Te K Tseng; Gary R Klimpel; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-06       Impact factor: 3.738

8.  Moxifloxacin in the therapy of experimental pneumococcal meningitis.

Authors:  H Schmidt; A Dalhoff; K Stuertz; F Trostdorf; V Chen; O Schneider; C Kohlsdorfer; W Brück; R Nau
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Quantitation and biological properties of released and cell-bound lipooligosaccharides from nontypeable Haemophilus influenzae.

Authors:  X X Gu; C M Tsai; M A Apicella; D J Lim
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

10.  An enteric pathogen Salmonella enterica serovar Typhimurium suppresses tumor growth by downregulating CD44high and CD4T regulatory (Treg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth.

Authors:  T Liu; A K Chopra
Journal:  Cancer Gene Ther       Date:  2009-08-28       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.